Individualizing Therapy for Non–Small-Cell Lung Cancer: A Paradigm Shift from Empiric to Integrated Decision-Making
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference20 articles.
1. Phase III, randomized, open-label, first-line study of gefitinib (C) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS);Mok;Ann Oncol,2008
2. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006
3. Outcomes for elderly, advancedstage non–small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599;Ramalingam;J Clin Oncol,2008
4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005
5. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing;Genes;2022-04-29
2. Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available;Journal of Clinical Pathology;2021-08-16
3. Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm;Journal of Clinical Pathology;2018-05-24
4. Systemic Treatment Patterns With Advanced or Recurrent Non–small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study;Clinical Therapeutics;2017-06
5. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell;Tumor Biology;2016-04-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3